Fact Sheets
SELECTED MEDICINES IN DEVELOPMENT FOR HEART DISEASE AND STROKE¹
Click here to read the news release
Click here to read the report
Reducing Heart Attack Deaths – Each year, 157,000 Americans die of heart attacks. A new medicine in development offers hope of reducing that statistic. It’s a monoclonal antibody that targets the proteins that injure the heart after an attack. In clinical trials, the medicine reduced heart attack deaths.
Restoring Heart Function – More than 5.2 million Americans are living with congestive heart failure. Heart failure is a progressive deterioration of the heart muscle. A new treatment in development delivers human stem cells (myoblasts) to form new heart muscle to restore cardiac function to the patient’s heart.
Pulmonary Arterial Hypertension: A progressive and potentially life-threatening condition that involves high blood pressure and structural changes in the walls of the pulmonary arteries, the blood vessels that connect the heart to the lungs. The condition, which causes shortness of breath, limits activity and shortens life-expectancy. A new medicine in development may be able to reduce these effects. An oral endothelin A receptor antagonist is designed to block a protein involved in constricting blood vessels and increasing pressure on the pulmonary arteries.
Preventing Strokes: Two million Americans suffer from atrial fibrillation, in which the two small upper chambers of the heart quiver instead of beating effectively. Blood in these quivering chambers can clot, travel to an artery in the brain and cause a stroke. About 15 percent of strokes in the U.S. occur in people with atrial fibrillation. A new medicine in development is designed to prevent strokes in people with this condition. It is an oral, direct Factor Xa inhibitor (an anticoagulant that limits blood clotting) that acts at the central point in the coagulation cascade, to regulate thrombin generation, which leads to clot formation.
Managing Cholesterol: Low levels of high-density lipoprotein (HDL), or “good”, cholesterol are thought to put patients at risk of coronary artery disease and heart attacks. A new vaccine in development is designed to prevent the transfer of “good” cholesterol to “bad” low-density lipoprotein (LDL) cholesterol, thus keeping “good” cholesterol levels high. The vaccine stimulates the body to produce antibodies to a protein responsible for the transfer process between HDL and LDL cholesterol.
Click here to read the release
Click here to read the report
¹ All disease facts from the American Heart Association. 0514107
Click here to read the news release
Click here to read the report
Reducing Heart Attack Deaths – Each year, 157,000 Americans die of heart attacks. A new medicine in development offers hope of reducing that statistic. It’s a monoclonal antibody that targets the proteins that injure the heart after an attack. In clinical trials, the medicine reduced heart attack deaths.
Restoring Heart Function – More than 5.2 million Americans are living with congestive heart failure. Heart failure is a progressive deterioration of the heart muscle. A new treatment in development delivers human stem cells (myoblasts) to form new heart muscle to restore cardiac function to the patient’s heart.
Pulmonary Arterial Hypertension: A progressive and potentially life-threatening condition that involves high blood pressure and structural changes in the walls of the pulmonary arteries, the blood vessels that connect the heart to the lungs. The condition, which causes shortness of breath, limits activity and shortens life-expectancy. A new medicine in development may be able to reduce these effects. An oral endothelin A receptor antagonist is designed to block a protein involved in constricting blood vessels and increasing pressure on the pulmonary arteries.
Preventing Strokes: Two million Americans suffer from atrial fibrillation, in which the two small upper chambers of the heart quiver instead of beating effectively. Blood in these quivering chambers can clot, travel to an artery in the brain and cause a stroke. About 15 percent of strokes in the U.S. occur in people with atrial fibrillation. A new medicine in development is designed to prevent strokes in people with this condition. It is an oral, direct Factor Xa inhibitor (an anticoagulant that limits blood clotting) that acts at the central point in the coagulation cascade, to regulate thrombin generation, which leads to clot formation.
Managing Cholesterol: Low levels of high-density lipoprotein (HDL), or “good”, cholesterol are thought to put patients at risk of coronary artery disease and heart attacks. A new vaccine in development is designed to prevent the transfer of “good” cholesterol to “bad” low-density lipoprotein (LDL) cholesterol, thus keeping “good” cholesterol levels high. The vaccine stimulates the body to produce antibodies to a protein responsible for the transfer process between HDL and LDL cholesterol.
Click here to read the release
Click here to read the report
¹ All disease facts from the American Heart Association. 0514107